As bankrupt homegrown company Athenex Inc. fades away, where does Western New York go from here in its hunt for a biotech blockbuster? That's unclear, though having a lineup of promising companies in ...

A monumental achievement for ImmunityBio, Inc., occurred earlier this week, leaving the door open for potential major benefits to the Dunkirk community. Earlier this week, the Food and Drug ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min ImmunityBio plans to use the ...

We came across a bullish thesis on ImmunityBio, Inc. on Investment Ideas by Antonio’s Substack by Antonio Linares. In this article, we will summarize the bulls’ thesis on IBRX. ImmunityBio, Inc.’s ...

ANKTIVA ® Drug Substance completed and released with two-year storage stability data sufficient for 170,000 doses of ANKTIVA product ImmunityBio’s 400,000 square foot GMP fill-finish facility in ...

Town of Dunkirk resident Sue Hazelton is never shy to bring something before the Town Board during public comments. At the most recent meeting, her question for the Board was one that many in the ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min With a deficit of $2.5 billion ...

ImmunityBio, Inc. (NASDAQ:IBRX) shares are trading higher Friday after the company announced overall survival results in its QUILT 3.055 study. ImmunityBio said the QUILT 3.055 trial shows median ...

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX) announced today that its 2024 Annual Meeting of Stockholders will be held on Tuesday, June 11, 2024 at 9:30 a.m. Pacific Time.

Over 400,000 square foot, state-of-the-art, finish-fill and lyophilization facility enables one billion doses of RNA and adjuvant vaccine production Newly constructed Current Good Manufacturing ...

As it continues construction, ImmunityBio noted in a quarterly regulatory filing that it believes governmental funding will assist in funding a portion of the further build-out in Dunkirk. As of March ...

CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX) announced today that the drug substance (DS) has been completed and successfully qualified for “fill finish” (filling vials and ...